Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
Funding for research on behavioral interventions testing efficacy, clinical trials, behavior change mechanisms, and optimizing drug abuse treatment, adherence, interventions for comorbidities, HIV prevention, and technology-enhanced treatments.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 5, 2025 (New) | March 5, 2025 (Renewal/Resubmission/Revision) | May 7, 2025 (AIDS-related)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports research on behavioral and integrative interventions for drug abuse, including efficacy trials, mechanism studies, treatment optimization, and technology-enhanced approaches.
Key Information: Applications must address Stages I–III of behavioral intervention development; alcohol use disorder as a primary outcome is not responsive.
Description
This opportunity from the National Institutes of Health (NIH), led by the National Institute on Drug Abuse (NIDA), funds research on the development, testing, and optimization of behavioral and integrative treatments for drug and substance use, misuse, and dependence. The program supports research across Stages I–III of behavioral intervention development, including efficacy trials, mechanism studies, dose-response, treatment sequencing, and the integration of behavioral and pharmacological approaches. Projects may also address interventions to improve treatment adherence, prevent HIV among individuals in drug abuse treatment, and leverage technology to enhance intervention delivery and sustainability.
The program encourages applications that:
- Develop or refine behavioral interventions (including psychotherapies, cognitive, family, skills training, and exercise therapies).
- Test interventions in both research and real-world (community) settings.
- Examine mechanisms of behavior change, including biological, cognitive, social, and neurobiological factors.
- Integrate behavioral and pharmacological treatments.
- Use innovative technologies (e.g., digital therapeutics, mobile apps, virtual reality, AI) to enhance interventions.
- Address adherence to treatment and medications for substance use disorders (SUDs) and HIV.
- Target special populations (e.g., adolescents, pregnant women, individuals with comorbidities, those with chronic pain).
- Adapt interventions for health disparities populations.
Applications focused on alcohol use disorder as the primary outcome are not responsive to this opportunity.
